Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
A person associated with AVTX has filed a notice of intent to sell common stock. The planned sale covers 3,749 shares of AVTX common stock, with an indicated aggregate market value of 74,762.10, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 17, 2026 on the NASDAQ market.
The shares come from multiple sources, including 2,876 shares acquired via an exercise of options under a registered plan on August 17, 2026 and several smaller lots (such as 450 shares and 417 shares) purchased through an Employee Stock Purchase Plan between 2020 and 2025.
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Avalo Therapeutics, Inc.
As of June 30, 2026, the reporting persons may be deemed to beneficially own 1,862,250 shares of Avalo Therapeutics common stock, representing 3.54% of the outstanding class. All reported shares are held by funds and separately managed accounts controlled by Nantahala, with the reporting persons having shared voting and dispositive power over these shares and no sole voting or dispositive power. Each of Harkey and Mack files as a control person in respect of shares beneficially owned by Nantahala, which is described as an investment adviser.
Caligan Partners LP and David Johnson report beneficial ownership of Avalo Therapeutics, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 3,163,866 shares of common stock, representing 5.9% of the class, based on 53,629,989 shares outstanding as of August 3, 2026.
The reporting persons have shared voting and dispositive power over all 3,163,866 shares and no sole voting or dispositive power. The shares are held by certain funds and accounts for which Caligan serves indirectly as investment manager, with David Johnson as Managing Partner of Caligan and Managing Member of its general partner.
RA Capital Management, L.P. and affiliated entities report beneficial ownership of 3,483,099 shares of Avalo Therapeutics, Inc. common stock as of June 30, 2026, representing 6.3% of the class. The holding consists of 1,000,000 common shares directly owned by RA Capital Healthcare Fund, L.P. and Series C preferred stock convertible into 2,483,099 common shares.
The ownership percentage is calculated based on 52,900,692 common shares outstanding plus the 2,483,099 shares issuable upon conversion of the preferred shares. Voting and dispositive power over the Fund’s holdings has been delegated to RA Capital, and the Fund disclaims beneficial ownership for Section 13(d) purposes. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners under Section 13(d) but each disclaims beneficial ownership except for determining reporting obligations.
Avalo Therapeutics, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert reporting aggregated holdings in Avalo’s common stock. As of June 30, 2026, these reporting persons collectively beneficially owned 2,801,545 shares of common stock, including shares issuable upon conversion of preferred stock, representing approximately 5.3% of the outstanding common stock.
The group holds 726 shares of Series C Non-Voting Convertible Preferred Stock, initially convertible into an aggregate of 726,000 common shares, subject to a 9.99% Beneficial Ownership Limitation, which did not restrict conversion at that time. The ownership percentages are based on 52,565,572 common shares outstanding as of May 8, 2026, plus the relevant convertible shares.
T. Rowe Price Investment Management, Inc. filed an amended ownership report for Avalo Therapeutics Inc. common stock. The firm reports beneficial ownership of 3,670 shares, representing 0.0% of the class, all with sole voting and dispositive power. It states that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
Avalo Therapeutics, Inc. received an amended Schedule 13G filing indicating that Avoro Capital Advisors LLC and Behzad Aghazadeh collectively report beneficial ownership of 2,333,333 shares of Avalo common stock. This represents 4.44% of the outstanding common stock, based on 52,565,572 shares outstanding as of May 8, 2026. The reporting persons each have sole voting and sole dispositive power over these shares and no shared voting or shared dispositive power. The stake is held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and the filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 3,610,000 shares of Avalo Therapeutics, Inc. common stock, representing 6.87% of the class as of June 30, 2026.
The reporting persons have shared voting and dispositive power over all 3,610,000 shares and no sole voting or dispositive power. The ownership percentage is based on 52,565,572 shares outstanding as of May 8, 2026, as disclosed by Avalo. David Kroin may be considered a control person of Deep Track Capital, LP, and the parties have agreed to a joint filing.
Avalo Therapeutics, Inc. is reported to have 2,900,000 shares of its common stock beneficially owned through Affinity Healthcare Fund, LP, with investment decisions made by Affinity Asset Advisors, LLC and its managing member, Michael Cho. As of June 30, 2026, these reporting persons held approximately 5.5% of Avalo’s outstanding common stock, based on 52,900,692 shares outstanding. They report sole voting and dispositive power over all 2,900,000 shares and no shared voting or dispositive power.